Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?
Author:
Visseaux Benoit12ORCID, Assoumou Lambert3, Mahjoub Nadia4, Grude Maxime5, Trabaud Mary-Anne6, Raymond Stéphanie7ORCID, Wirden Marc8, Morand-Joubert Laurence9, Roussel Catherine10, Montes Brigitte11, Bocket Laurence12, Fafi-Kremer Samira13, Amiel Corinne14, De Monte Anne15, Stefic Karl16ORCID, Pallier Coralie17, Tumiotto Camille18, Maillard Anne19, Vallet Sophie20, Ferre Virginie21, Bouvier-Alias Magali22, Dina Julia23, Signori-Schmuck Anne24, Carles Marie-Josée25, Plantier Jean-Christophe26ORCID, Meyer Laurence27, Descamps Diane12, Chaix Marie-Laure2428, Roussel C, Le Guillou-Guillemette H, Ducancelle A, Courdavault L, Alloui C, Honore P, Lepiller Q, Bettinger D, Bellecave P, Pinson-Recordon P, Tumiotto C, Vallet S, Payan C, Duthe J C, Leroux M, Dina J, Vabret A, Mirand A, Henquell C, Bouvier-Alias M, Simohamed A, Dos Santos G, Yerly S, Gaille C, Caveng W, Chapalay S, Calmy A, Signori-Schmuck A, Morand P, Pallier C, Raho-Moussa M, Mole M, Dulucq M-J, Bocket L, Alidjinou K, Ranger-Rogez S, Trabaud M A, Icard V, Tardy J C, Tamalet C, Delamare C, Montes B, Schvoerer E, Fenaux H, Rodallec A, André-Garnier E, Ferré V, De Monte A, Guigon A, Guinard J, Descamps D, Charpentier C, Visseaux B, Peytavin G, Tremaux P, Avettand-Fenoel V, Soulié C, Malet I, Wirden M, Marcelin A G, Calvez V, Flandre P, Assoumou L, Costagliola D, Morand-Joubert L, Lambert-Niclot S, Fofana D, Boukli N, Delaugerre C, Chaix M L, Mahjoub N, Amiel C, Giraudeau G, Beby-Defaux A, Plainchamp D, Maillard A, Alessandri-Gradt E, Leoz M, Plantier J C, Gantner P, Delagreverie H, Fafi-Kremer S, Fischer P, Raymond S, Izopet J, Chiabrando J, Stefic K, Barin F, Fajole G, Burgault O, Marque-Juillet S,
Affiliation:
1. IAME, Université de Paris, AP-HP, UMR 1137, INSERM, Virology, Hôpital Bichat, AP-HP, Paris, France 2. Centre National de Référence VIH, Paris, France 3. INSERM, Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France 4. Hopital Saint-Louis, Virology, Paris, France 5. AP-HP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France 6. Hôpital de la Croix Rousse, Virology, Lyon, France 7. CHU Purpan, Virology, Toulouse, France 8. CHU Pitié-Salpêtrière, Virology, Paris, France 9. AP-HP, Hôpital Saint-Antoine, Laboratoire de virologie, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, (iPLESP), Paris, France 10. CHU Amiens, Virology, Amiens, France 11. CHU Montpellier, Virology, Montpellier, France 12. CHU Lille, Virology, Lille, France 13. CHU Strasbourg, Virology, Strasbourg, France 14. Hopital Tenon, Virology, Paris, France 15. CHU Nice, Virology, Nice, France 16. INSERM U1259, Université de Tours, CHU Tours, Virology, Tours, France 17. Hopital Paul Brousse HUPS, Villejuif, France 18. CHU Bordeaux, Virology, Bordeaux, France 19. CHU Rennes, Virology, Rennes, France 20. CHU Brest, Virology, Brest, France 21. CHU Nantes, Virology, Nantes, France 22. CHU Henri Mondor, Virology, Créteil, France 23. CHU Caen, Caen, France 24. CHU Grenoble Alpes, Virology, Grenoble, France 25. CHU-Nimes, Virology, Nimes, France 26. Normandie University, UNIROUEN Rouen, EA2656, Rouen University Hospital, Virology, Rouen, France 27. INSERM SC10 US19, Villejuif, INSERM CESP U1018, Université Paris Sud, Université Paris Saclay, France 28. Université de Paris, INSERM U944, Paris, France
Abstract
Abstract
Objectives
Patients with primary HIV-1 infection (PHI) are a particular population, giving important insight about ongoing evolution of transmitted drug resistance-associated mutation (TDRAM) prevalence, HIV diversity and clustering patterns. We describe these evolutions of PHI patients diagnosed in France from 2014 to 2016.
Methods
A total of 1121 PHI patients were included. TDRAMs were characterized using the 2009 Stanford list and the French ANRS algorithm. Viral subtypes and recent transmission clusters (RTCs) were also determined.
Results
Patients were mainly MSM (70%) living in the Paris area (42%). TDRAMs were identified among 10.8% of patients and rose to 18.6% when including etravirine and rilpivirine TDRAMs. Prevalences of PI-, NRTI-, first-generation NNRTI-, second-generation NNRTI- and integrase inhibitor-associated TDRAMs were 2.9%, 5.0%, 4.0%, 9.4% and 5.4%, respectively. In a multivariable analysis, age >40 years and non-R5 tropic viruses were associated with a >2-fold increased risk of TDRAMs. Regarding HIV diversity, subtype B and CRF02_AG (where CRF stands for circulating recombinant form) were the two main lineages (56% and 20%, respectively). CRF02_AG was associated with higher viral load than subtype B (5.83 versus 5.40 log10 copies/mL, P = 0.004). We identified 138 RTCs ranging from 2 to 14 patients and including overall 41% from the global population. Patients in RTCs were younger, more frequently born in France and more frequently MSM.
Conclusions
Since 2007, the proportion of TDRAMs has been stable among French PHI patients. Non-B lineages are increasing and may be associated with more virulent CRF02_AG strains. The presence of large RTCs highlights the need for real-time cluster identification to trigger specific prevention action to achieve better control of the epidemic.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|